Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
about
Vaccine therapies in malignant gliomaDifferential expression and clinical significance of glioblastoma mRNA expression profiles in Uyghur and Han patients in Xinjiang provinceVaccine therapies for patients with glioblastoma.Immunotherapeutic advancements for glioblastoma.A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
P2860
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@en
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@nl
type
label
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@en
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@nl
prefLabel
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@en
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@nl
P2093
P2860
P50
P1476
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy.
@en
P2093
Arthur Melms
Claudia Trautwein
Jürgen Honegger
Lisa Christ
Marian Christoph Neidert
Nico Trautwein
Oliver Schoor
Pierre-Yves Dietrich
P2860
P2888
P304
P356
10.1007/S11060-012-1028-8
P577
2012-12-23T00:00:00Z